---
title: "Cytokinetics Scores A First-Ever In Its Rivalry Against Bristol Myers"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297320146.md"
description: "On Friday, Cytokinetics achieved a significant milestone by securing the first victory in a Phase 3 trial for non-obstructive hypertrophic cardiomyopathy. This marks a pivotal moment in the competition against Bristol Myers."
datetime: "2026-08-28T11:35:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297320146.md)
  - [en](https://longbridge.com/en/news/297320146.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297320146.md)
generator: "portal-rs"
---

# Cytokinetics Scores A First-Ever In Its Rivalry Against Bristol Myers

On Friday, Cytokinetics achieved a significant milestone by securing the first victory in a Phase 3 trial for non-obstructive hypertrophic cardiomyopathy. This marks a pivotal moment in the competition against Bristol Myers.

### Related Stocks

- [CYTK.US](https://longbridge.com/en/quote/CYTK.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [232,697 Shares in Bristol Myers Squibb Company $BMY Acquired by Beacon Pointe Advisors LLC](https://longbridge.com/en/news/297394340.md)
- [BUZZ-Cytokinetics rises after heart disease drug shows promise in late-stage study](https://longbridge.com/en/news/297310247.md)
- [Cytokinetics Investors Weigh Safety Data From Pivotal Trial](https://longbridge.com/en/news/297549493.md)
- [Cytokinetics to file FDA sNDA for aficamten in non-obstructive HCM in Q4 2026](https://longbridge.com/en/news/297300803.md)
- [Cytokinetics posts MAPLE-HCM presentation on aficamten vs metoprolol in obstructive hypertrophic cardiomyopathy](https://longbridge.com/en/news/297405384.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**